Note FDA regulations on PSA assays

被引：0
|
作者：
Knapp, MA
机构：
来源：
LABORATORY MEDICINE | 1996年 / 27卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：214 / 214
页数：1
相关论文
共 50 条
  • [41] A process for compliance with revisions to FDA regulations
    Johnson, DW
    Coleman, N
    Kepler, K
    Millar, W
    [J]. DRUG INFORMATION JOURNAL, 1998, 32 (02): : 393 - 399
  • [42] FDA GOALS IN LABELING AND ADVERTISING REGULATIONS
    HAUSER, J
    [J]. FOOD DRUG COSMETIC LAW JOURNAL, 1967, 22 (05): : 300 - 303
  • [43] PSA ASSAYS IN PROSTATE-CANCER
    PONS, D
    RAMAIOLI, A
    NAMER, M
    GALLAND, A
    KREBS, BP
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (08): : 1247 - 1247
  • [44] Standardization and quality assessment of PSA assays
    Sturgeon, Catherine M.
    [J]. CLINICA CHIMICA ACTA, 2007, 381 (01) : 102 - 102
  • [45] Comparison of PSA and free PSA assays on ACS 180 and AxSYM.
    Berlitz, FA
    [J]. CLINICAL CHEMISTRY, 2000, 46 (06) : A154 - A155
  • [46] CLINICAL IMPACT OF USE OF DIFFERENT PSA ASSAYS IN DIAGNOSING PSA RECURRENCE
    Kwiatkowski, Maciej, Sr.
    Baumgartner, Martin K., Sr.
    Arndt, Brigitte, Sr.
    Lehmann, Kurt, Sr.
    Huber, Andreas, Sr.
    Recker, Franz, Sr.
    [J]. JOURNAL OF UROLOGY, 2009, 181 (04): : 652 - 652
  • [47] USPSTF and FDA: PSA and 5ARIs
    Klotz, Laurence H.
    [J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2011, 5 (06): : 373 - 374
  • [48] CLINICAL IMPACT OF USE OF DIFFERENT PSA ASSAYS IN DIAGNOSING PSA RECURRENCE
    Kwiatkowski, M.
    Baumgartner, M.
    Arndt, B.
    Lehmann, K.
    Huber, A.
    Recker, F.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 296 - 296
  • [49] FDA SYMPOSIUM ASSAYS PHOTOCHEMICAL TOXICITY
    GOLDEMBERG, R
    [J]. DRUG & COSMETIC INDUSTRY, 1981, 128 (05): : 44 - &
  • [50] POSSIBILITY FOR ERROR IN FDA DIFFUSION ASSAYS
    FOGLESONG, MA
    KAVANAGH, F
    DIETZ, JV
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1979, 68 (06) : 797 - 798
12345